BRCA2 and colorectal cancer: BRCA2−/− colorectal cancer cells DLD1 co-treated with olaparib and NSC617145 also displayed a greater reduction in proliferation than that due to an additive effect of the two drugs acting independently (Supplementary Fig. 14b).